Administration of AZD6738
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),
Conditions
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
Trial Timeline
Nov 1, 2013 → Dec 1, 2013
NCT ID
NCT01955668About Administration of AZD6738
Administration of AZD6738 is a phase 1 stage product being developed by AstraZeneca for 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),. The current trial status is completed. This product is registered under clinical trial identifier NCT01955668. Target conditions include 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01955668 | Phase 1 | Completed |